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Analysis of GNAS1 and Overlapping Transcripts Identifies
the Parental Origin of Mutations in Patients with Sporadic
Albright Hereditary Osteodystrophy and Reveals a Model
System in Which to Observe the Effects of Splicing Mutations
on Translated and Untranslated Messenger RNA
Sarah J. Rickard and Louise C. Wilson
Clinical and Molecular Genetics Unit, Institute of Child Health, and Great Ormond Street Hospital NHS Trust, London
Albright hereditary osteodystrophy (AHO) is caused by heterozygous deactivating GNAS1 mutations. There is a
parent-of-origin effect. Maternally derived mutations are usually associated with resistance to parathyroid hormone
termed “pseudohypoparathyroidism type Ia.” Paternally derived mutations are associated with AHO but usually
normal hormone responsiveness, known as “pseudo-pseudohypoparathyroidism.” These observations can be ex-
plained by tissue-specificGNAS1 imprinting. Regulation of the genomic region that encompassesGNAS1 is complex.
At least three upstream exons that splice to exon 2 of GNAS1 and that are imprinted have been reported. NESP55
is exclusively maternally expressed, whereas exon 1A and XLas are exclusively paternally expressed. We set out
to identify the parental origin of GNAS1 mutations in patients with AHO by searching for their mutation in the
overlapping transcripts. This information would be of value in patients with sporadic disease, for predicting their
endocrine phenotype and planning follow-up. In doing so, we identified mutations that resulted in nonsense-mediated
decay of the mutant Gsa transcript but that were detectable in NESP55 messenger RNA (mRNA), probably because
they lie within its 3′ untranslated region. Analysis of the NESP55 transcripts revealed the creation of a novel splice
site in one patient and an unusual intronic mutation that caused retention of the intron in a further patient, neither
of which could be detected by analysis of the Gsa complementary DNA. This cluster of overlapping transcripts
represents a useful model system in which to analyze the effects that mutant sequence has on mRNA—in particular,
splicing—and the mechanisms of nonsense-mediated mRNA decay.
Introduction
Albright hereditary osteodystrophy (AHO[MIM103580])
is characterized by short adult stature, obesity, brachy-
dactyly, and ectopic ossifications in ∼60% of patients
(for review, see Wilson and Trembath 1994). It is fre-
quently associated with mild-to-moderate mental hand-
icap. A proportion of patients with AHOhave associated
end-organ resistance to parathyroid hormone (PTH),
known as “pseudohypoparathyroidism type I” (PHP Ia).
Those who have AHO and normal endocrine respon-
siveness are said to have “pseudo-pseudohypoparathy-
roidism” (PPHP).
Patients with PHP Ia usually manifest hypocalcemia
together with hyperphosphatemia and raised PTH (in the
Received November 5, 2002; accepted for publication January 16,
2003; electronically published March 6, 2003.
Address for correspondence and reprints: Dr. LouiseWilson,Clinical
and Molecular Genetics Unit, Institute of Child Health, 30 Guilford
Street, London, WC1N 1EH, United Kingdom. E-mail: l.wilson@ich
.ucl.ac.uk
 2003 by The American Society of Human Genetics. All rights reserved.
0002-9297/2003/7204-0017$15.00
presence of normal renal function and 25-hydroxycho-
lecalciferol) at some point in childhood. In addition,
they often have clinically significant thyroid-stimulating
hormone (TSH) resistance resulting in hypothyroidism
(Levine et al. 1983). For reasons that are not clear, these
patients frequently have intermittent prolonged periods
of normocalcemia and normal thyroid function. As a
result, it can be difficult to determine whether a normo-
calcemic, euthyroid patient with AHO has the PHP Ia
form or the PPHP form, although PTH levels are usually
elevated in patients with PHP Ia. In the past, the PHP
Ia and PPHP forms could be distinguished by PTH-
stimulation testing, which was not possible here since
the supply of synthetic PTH for human injection was
discontinued.
Both the PHP Ia and PPHP forms of AHO are
caused by heterozygous deactivating mutations with-
in the GNAS1 gene, located on chromosome 20q13.
GNAS1 consists of 13 coding exons, from which four
common isoforms are generated through alternative
splicing of exon 3 and use of alternative splice-acceptor
sites one codon apart in exon 4 (Kozasa et al. 1988).
A variety of different frameshift, nonsense, and mis-
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Figure 1 Schematic representation of the GNAS1 cluster, including exons 1–13 ofGNAS1 and upstream imprinted exons NESP55, XLas,
and exon 1A. a, Summary of imprinting. Arrows above and below depict paternally and maternally expressed transcripts, respectively. The
transcripts for Gsa and XLas have ORFs starting in their unique 5′ exons and ending in exon 13. Exons 2–13 of GNAS1 lie within the 3′ UTR
of NESP55. Exon 1A is probably not translated. b, Location of primers used to amplify the Gsa, NESP55, and exon 1A transcripts (not to scale).
sense mutations throughout the gene have been re-
ported (for review, see Aldred and Trembath 2000).
GNAS1 is widely expressed and encodes the a subunit
of the heterotrimeric G protein, Gs, which transduces
signals between certain cell-surface receptors (includ-
ing those for PTH, TSH, and thyrotropin-releasing
hormone) and intracellular adenylyl cyclase (for re-
view, see Bourne and Stryer 1992). Patients with either
form of AHO have an ∼50% reduction in bioactivity
of the Gsa subunit in all tissues measured, including
erythrocytes, lymphocytes, platelets, and fibroblasts
(Farfel and Bourne 1980; Levine et al. 1980; Bourne
et al. 1981; Farfel et al. 1982). In families in which
AHO is segregating, the strongest predictor of the en-
docrine phenotype is the parent of origin (Davies and
Hughes 1993). Maternal transmission is usually as-
sociated with the PHP Ia form, and paternal trans-
mission is usually associated with the PPHP form, al-
though there has been an exception (Schuster et al.
1994). These observations are best explained by a tis-
sue-specific imprinting model in which GNAS1 is bial-
lelically expressed in most tissues but maternally ex-
pressed in certain cells, such as those of the proximal
renal tubule. The AHO phenotype results from a gen-
eral 50% Gsa-bioactivity reduction caused by deac-
tivating mutations of either allele, whereas associated
PHP Ia occurs only if the maternal allele is mutated,
since that is the only allele expressed in the imprinted
tissues. Support for this model has come from Gnas
knockout mice, from mice with uniparental disomy for
the homologous region encompassing Gnas, and from
studies of human pituitary and thyroid (Yu et al. 1998;
Peters et al. 1999; Hayward et al. 2001; Germain-Lee
et al. 2002; Mantovani et al. 2002).
Regulation of the genomic region that encompasses
GNAS1 is complex (see fig. 1a). Three overlapping
transcripts, each of which has an alternative upstream
exon spliced to exons 2–13 of GNAS1, have been re-
ported. Exon 1A lies ∼2.5 kb upstream of GNAS1
exon 1. Exon 1A–containing transcripts are exclu-
sively paternally expressed in a wide range of tissues
and are probably not translated. Exon 1A appears to
be intimately involved in the tissue-specific imprinting
ofGNAS1, since individuals with abnormal imprinting
of exon 1A—specifically, an unmethylated maternal al-
lele—have isolated PTH resistance known as “PHP Ib”
(Liu et al. 2000). Another transcript, known as “extra-
large Gsa” (XLas), comprises a novel exon, 35 kb up-
stream of GNAS1 exon 1, that forms a continuous
ORF with exons 2–13 of GNAS1; this transcript is
also exclusively paternally expressed. The third tran-
script, NESP55 (a neuroendocrine secretory protein),
has a novel exon ∼14 kb upstream of XLas and is
spliced to GNAS1 exons 2–13, which appear to lie
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within its 3′ UTR. The function of NESP55 is not
known, but it appears to be exclusively maternally
expressed (Hayward et al. 1998). NESP55 is spanned
by a paternally expressed antisense transcript that
originates upstream of XLas and that is likely to be
involved in suppressing the paternal NESP55 allele
(Hayward and Bonthron 2000). Further complexity
is suggested by the presence of an alternative 3′ exon,
contained within intron 3 of GNAS1, that includes
an alternative stop codon and polyadenylation site
(Crawford et al. 1993).
We set out to test whether these overlapping imprint-
ed transcripts could be used to determine the parental
origin ofGNAS1mutations. That would be of potential
clinical value for predicting the endocrine phenotype in
patients with sporadic AHO and for quantifying the ex-
tent of the parental-origin effect, given that it may not
be absolute. Using a common polymorphism (c.393T/C)
in exon 5 ofGNAS1, we have confirmed that imprinting
of the NESP55 and exon 1A transcripts is conserved in
control lymphoblastoid cell lines.We have tested a cohort
of nine patients with AHO who have mutations in exons
2–13 of GNAS1 from whom lymphoblastoid cell lines
were available. In one patient known to have inherited
the condition from her mother and in a further five pa-
tients with de novo mutations who have PHP Ia, we have
demonstrated that the mutation is present in the NESP55
transcript but not in the exon 1A–containing transcript,
confirming that it originated on the maternal GNAS1
allele. In one patient with PPHP in whom paternal origin
has been demonstrated previously (Wilson et al. 1994)
and in two further patients with probable PPHP, paternal
origin was confirmed.
Four of the patients in the cohort that we studied had
mutations predicted to cause frameshifts and premature
termination codons. These mutations were not detectable
in the Gsa cDNA, presumably owing to nonsense-me-
diated decay (NMD) of mRNA. However, themutations,
which were all maternally derived, were detected in the
NESP55 transcripts, where they lie within the 3′ UTR.
In one patient, a single-nucleotide substitution at position
11 from the intron 4 splice-acceptor site appears to
have resulted in retention of intron 4 in the NESP55
transcript. In another patient, a single-nucleotide change
at position1 of the intron 7 splice-acceptor site resulted
in the use of a novel splice-acceptor site 1 nt downstream
in the NESP55 transcript.
Subjects and Methods
Patients
Patients with AHO were recruited through U.K. clin-
ical geneticists. In some instances, affected parents were
ascertained after the diagnosis of AHO in their child.
Most patients were seen at home for examination and
for collection of samples for baseline biochemistry, in-
cluding urea, electrolytes, calcium, phosphate, albu-
min, creatinine, and thyroid function, as well as lym-
phocyte DNA and lymphoblastoid cell lines. Samples
for PTH were not collected, because of the requirement
for rapid separation of the plasma. When available,
additional information was obtained from the local
clinicians and hospital notes. For patients who were
treated with vitamin D preparations and/or thyroxine,
details of their biochemical results at presentation were
obtained when possible from notes or the referring cli-
nician. Ethical committee approval was obtained for
the study.
DNA Preparation
DNA and RNA were extracted from Epstein-Barr vi-
rus–transformed lymphoblastoid cell lines, which were
grown in RPMI media (Gibco BRL) with 10% fetal
bovine serum (Sigma), 1% L-Glutamate (Gibco BRL),
and 0.1% penicillin/streptomycin (Sigma). DNA was
extracted using standard methods.
RNA Extraction and cDNA Synthesis
Total RNA was extracted from lymphoblast cell pellets
and fetal tissue by using Trizol, following the manufac-
turer’s instructions (Gibco BRL). Each sample was treat-
ed with DNase (Gibco BRL), and cDNA synthesis was
performed on ∼2 mg of total RNA by using Superscript
II (Gibco BRL), following the manufacturer’s instruc-
tions. The reverse-transcriptase reaction contained both
an oligo dT and a random nonomer primer. The result-
ing cDNA products were amplified using standard
hypoxanthine-guanine phosphoribosyltransferase–gene
primers and were visualized on a 2% agarose gel to
detect genomic contamination.
Screening of GNAS1 Exons 2–13 and Adjacent
Introns, by Use of Denaturing High-Performance
Liquid Chromatography (DHPLC)
Previously reported mutations were confirmed in
the cell lines by sequencing of the relevant exon, us-
ing BigDye terminator technology (Applied Biosys-
tems), and were run on an ABI 377 DNA Sequencer.
Screening for unknown mutations was performed us-
ing DHPLC (Transgenomic WAVE DNA Fragment
Analysis System). The optimal column temperatures
and acetonitrile gradients were calculated for each
fragment by using the WAVEMaker program (con-
ditions available on request). Each fragment was am-
plified using the primer sets and conditions listed in
table 1, with Hot Star Taq polymerase (Qiagen), fol-
lowing the manufacturer’s instructions. Any ampli-
cons exhibiting altered elution peaks were sequenced
as described above.
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Table 1
Primers and Conditions for Amplification of Gsa, NESP55, and Exon 1A Transcripts
Primer Name Primer Sequence
PCR Annealing
Temperature/No. of Cycles
GNAS4F ATG AAA GCA GTA CTC CTA ACT GA
GNAS5R GTG CCC ATG TGC AGG GCT GTC ACT CAT GTT 57C/30a
GNAS7F TGA GCC TGA CCT TGT AGA GAG ACA CA
GNAS8R GGT TAT TCC AGA GGG ACT GGG GTG AA 57C/30a
GNAS9F GGT TTC TTG ACA TTC ACC CCA G
GNAS10R CTC TAT AAA CAG TGC AGA CCA G 57C/30a
GNAS4F1 TGA GAG GGC AAC CAA AGT G
GNAS6R1 CCT TGG CAT GCT CAT AGA ATT 57C/30a
MET1F GGA ACA GTA AGA CCG AGG ACC
GNAS11R2 CTC AGG AGT AGT GTA GCG AGC A 62C/35a
NESP CTT AAC GCC CAC CAC CGC TC
GNAS11R2 CTC AGG AGT AGT GTA GCG AGC A 6, 34b
NESP5 TCG GAA TCT GAC CAC GAG CA
GNAS10R1 CAC GAA GAT GAT GGC AGT CAC 6, 34b
NESP5 TCG GAA TCT GAC CAC GAG CA
GNAS11R2 CTC AGG AGT AGT GTA GCG AGC A 6, 34b
NESP5 TCG GAA TCT GAC CAC GAG CA
GNAS13R2 TTA GAG CAG CTG GTA CTG ACG 63C/40a
NESPF2 GAA GGA GCC CAA GGA GGA GAA GCA GCG GC
GNAS11R2 CTC AGG AGT AGT GTA GCG AGC A 63C/35a
EX1ARNAF CTG CGT CAG GTG GCT GGC
GNAS10R1 CAC GAA GAT GAT GGC AGT CAC 64C/35a
EX1ARNAF CTG CGT CAG GTG GCT GGC
GNAS11R2 CTC AGG AGT AGT GTA GCG AGC A 64C/35a
a PCRs performed under the following conditions: 96C for 15 min (5 min for Megamix PCR premix), then
96C for 1 min, annealing temperature for 1 min, and 72C for 1 min for the number of cycles indicated.
b PCRs performed under the following conditions: 96C for 15 min (96C for 30 s, 66C for 30 s, and 72C
for 45 s) for 1 cycle, then repeated for 5 cycles with .5C decrement of annealing temperature, concluding with
96C for 30 s, 63C for 30 s, and 72C for 45 s for 34 cycles.
Imprinting Analysis of NESP55, Exon 1A, and Gsa
Transcripts in Lymphoblast and Fetal RNA
For the detection of heterozygotes for the exon 5 FokI
polymorphism (c.393T/C), DNA extracted from normal
lymphoblast cells and cDNA from fetal tissue sampleswas
amplified using primers GNAS4F/GNAS5R, for the DNA
samples, and GNAS4F1/GNAS6R1, for the cDNA sam-
ples, andMegamix PCR premix (Microzone) (table 1 and
fig. 1b). The products were digested with FokI (NEB) and
were separated on a 2% agarose gel. Seven heterozygous
normal control lymphoblast cDNA samples, two hetero-
zygous fetal cDNAs (lung and kidney), and cDNA from
patient AHO-33 were amplified for the NESP55, exon
1A, and Gsa transcripts, by using NESPF2/GNAS10R1,
EX1ARNAF/GNAS10R1, and MET1F/GNAS10R1, re-
spectively. The authenticity of each amplicon was verified
by sequencing as described above (see the previous sub-
section). A second nested PCR was performed on 2 ml of
the original product in a total reaction volume of 20 ml
with GNAS4F1 (5′-labeled with FAM)/GNAS6R1, using
Megamix PCR premix (Microzone). Ten microliters of
the PCR product was digested with FokI (NEB) and sep-
arated on a 4% polyacrylamide gel on an ABI 377 DNA
Sequencer.
Amplification and Sequencing of NESP55, Exon 1A,
and Gsa Transcripts
NESP55, exon 1A, and Gsa transcripts were ampli-
fied from cDNA in all patients by using the primer
combinations shown in table 2 and figure 1b. Primers
and conditions are shown in table 1. In some patients,
reamplification of the original NESP55 PCR by using
a second nested primer set, NESPF2/GNAS11R2, was
necessary. One and a half microliters of original NESP55
PCR product was reamplified in a total volume of 30
ml. All PCRs from cDNA were performed using Hot
Star Taq polymerase (Qiagen), following the manufac-
turer’s instructions. Exon 1A is GC rich, and all PCRs
required the use of Q buffer (supplied with Hot Star
Taq polymerase) and, also, the addition of 5% dimethyl
sulfoxide in the sequencing reaction. All PCR products
were sequenced using BigDye (Applied Biosystems)
with a 96C denaturing temperature and a 55C an-
nealing temperature, under conditions recommended in
the kit. Sequencing in the forward direction was per-
formed using NESPF2, EX1ARNAF, and nested prim-
ers GNAS4F1 (5′-TGA GAG GGC AAC CAA AGT G-
3′) and GNAS9F1 (5′-CAT GTT TGA CGT GGG TGG
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Table 2
Primer-Set Combinations for Gsa, NESP55, and Exon 1A cDNA Amplifications
PATIENT
PRIMER SET FOR
Gsa NESP55 Exon 1A
AHO-17 MET1F/GNAS11R2 NESP/GNAS11R2, re-PCR with NESPF2/GNAS11R2 EX1ARNAF/GNAS10R1
AHO-10 MET1F/GNAS11R2 NESP/GNAS11R2, re-PCR with NESPF2/GNAS11R2 EX1ARNAF/GNAS10R1
AHO-15 MET1F/GNAS11R2 NESP5/GNAS13R2, re-PCR with NESPF2/GNAS11R2 EX1ARNAF/GNAS11R2
AHO-29 MET1F/GNAS11R2 NESP5/GNAS13R2, re-PCR with NESPF2/GNAS11R2 EX1ARNAF/GNAS11R2
AHO-55 MET1F/GNAS11R2 NESP/GNAS11R2, re-PCR with NESPF2/GNAS11R2 EX1ARNAF/GNAS11R2
AHO-33 MET1F/GNAS11R2 NESP/GNAS11R2, re-PCR with NESPF2/GNAS11R2 EX1ARNAF/GNAS11R2
AHO-11 MET1F/GNAS11R2 NESP5/GNAS11R2 EX1ARNAF/GNAS10R1
AHO-278 MET1F/GNAS11R2 NESP5/GNAS10R1 EX1ARNAF/GNAS10R1
AHO-13 MET1F/GNAS11R2 NESP5/GNAS11R2 EX1ARNAF/GNAS11R2
NOTE.—For primer sequences and conditions, see table 1.
C-3′), and the reverse strands were sequenced with the
original PCR primer.
Results
GNAS1 Mutation Screening
Mutations were identified in nine patients from whom
lymphoblastoid cell lineswere available. Their clinical fea-
tures are summarized in table 3, and mutations are sum-
marized in table 4. All mutations are numbered according
to the cDNA sequence reported by Kozasa et al. (1988)
(see the Genome Database [GDB ID GDB:120628]).
AHO-17.—This patient with AHO and PHP has been
reported previously (Oude Luttikhuis et al. 1994). He
has a de novo 43-bp deletion (c.278del43bp), extending
from exon 4 across the splice-donor junction to intron 4,
that is predicted to result in exon 4 skipping, causing a
frameshift and premature termination six codons down-
stream in exon 5.
AHO-10.—This patient with AHO and PHP has been
reported previously (Yu et al. 1995). He has the common
4-bp deletion (c.565-568delGACT) in exon 7; this dele-
tion is predicted to result in a frameshift and premature
protein truncation. It has been shown by others that this
mutation is not expressed in mRNA, presumably because
of NMD (Weinstein et al. 1992). The mutation was not
present in his clinically normal mother. His father was
deceased but had no known features of AHO.
AHO-15.—This patient with AHO and PHP has a
GrA substitution (c.586-1GrA) at the splice-acceptor
site of intron 7. Samples from her parents were not avail-
able. This mutation has not been reported previously.
The mutation was predicted either to result in exon 8
skipping with a frameshift and premature termination
in exon 9 or to form a weak novel splice-acceptor site
1 base downstream, resulting in a single-nucleotide de-
letion with a frameshift and premature termination in
exon 8.
AHO-29.—This patient has AHO and evidence of re-
sistance to TSH, suggesting that she may have the PHP
form. Her mother and younger sister also have features
of AHO. She was found to have a c.725CrT transition
predicted to result in the nonconservative substitution
of threonine by isoleucine at amino acid residue 242 in
exon 10. This amino acid lies within one of the three
switch regions of Gsa that are involved in conformational
changes between the active and inactive states (Penning-
ton 1994). The mutation segregated with the AHO phe-
notype in the family and was not found in 300 unrelated
chromosomes screened.
AHO-55.—This patient with AHO and PHP has a
c.776ArT substitution predicted to result in the noncon-
servative substitution of glutamate by valine at amino acid
259 in exon 10. The mutation was not present in either
of his clinically normal parents and was not found in 300
unrelated chromosomes screened. This residue is highly
conserved across all Ga subunits and lies within the third
switch region of Gsa (Pennington 1994). The same amino
acid substitution has been reported previously and has
been shown to result in impaired adenylyl cyclase stim-
ulation (Ahmed et al. 1998; Warner et al. 1999).
AHO-33.—No mutations were identified in this pa-
tient with AHO and PHP, after screeningGNAS1 exons
2–13 and adjacent splice sites by SSCP and DHPLC and
sequencing of exon 1. She was heterozygous (/) for
the common FokI polymorphism in exon 5 in genomic
DNA. However, analysis of Gsa cDNA from her lym-
phoblast cell line showed that she was only expressing
her  allele. Her father was clinically normal and was
shown to be homozygous for the FokI  allele. Her
mother was deceased but was not known to have had
AHO. It was assumed that this patient had an uniden-
tified mutation on her maternally derived  allele, re-
sulting in NMD. Subsequent screening of the NESP55
transcript resulted in the identification of a single-nu-
cleotide substitution (IVS4:11ArG), within intron 4,
that causes retention of intron 4 and predicted premature
termination 21 codons into the intron-derived sequence
(fig. 2).
AHO-11.—This patient with AHO and PPHP, con-
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Table 4
Results of NESP55, Exon 1A, and Gsa cDNA Analysis
PATIENT (CLINICAL
PHENOTYPE)
GNAS1 MUTATIONa
(LOCATION)
CDNA RESULT FOR
NESP55 Exon 1A Gsa
AHO-17 (PHP Ia) c.278del43bp (exon 4) Exon 4 skipped allele only Normal allele only Normal allele only
AHO-10 (PHP Ia) c.565-568del4bp (exon 7) 565del4bp allele only Normal allele only Normal allele only
AHO-15 (PHP Ia) c.586-1GrA (intron 7) 586delG allele only Normal allele only Normal allele only
AHO-29 (PHP Ia) c.725CrT; T242I (exon 10) T242I allele only Normal allele only Normal/T242I allele
AHO-55 (PHP Ia) c.776ArG; E259V (exon 10) E259V allele only Normal allele only Normal/E259V allele
AHO-33 (PHP Ia) IVS4:11ArG Intron 4 retained allele only Normal allele only Normal allele only
AHO-11 (AHO) c.4321GrA (intron 5) Normal allele only Exon 5 skipped allele only Normal/exon 5 skipped allele
AHO-278 (AHO) c.4321GrA (intron 5) Normal allele only Exon 5 skipped allele only Normal/exon 5 skipped allele
AHO-13 (AHO) c.737TrC; F246S (exon 10) Normal allele only F246S allele only Normal/F246S allele
a Numbered according to the cDNA sequence reported by Kozasa et al. (1988) (see the Genome Database [GDB ID GDB:120628]).
firmed by PTH-stimulation testing, has been reported
previously (Wilson et al. 1994). She has a de novo sin-
gle-nucleotide substitution (c.4321GrA), affecting the
intron 5 splice-donor site, that is predicted to result in
exon 5 skipping, confirmed by analysis of the Gsa and
exon 1A cDNA transcripts (fig. 3b). Exon 5 skipping is
not associated with any frameshift.
AHO-278.—This patient has AHO with no history
of any symptomatic endocrine abnormality and has nor-
mal baseline calcium and thyroid function. He was as-
certained through his daughter, who has osteoma cutis.
His mutation is identical to that in patient AHO-11, to
whom he is unrelated.
AHO-13.—This patient with AHO has three children
with AHO and PHP Ia, all of whom developed hypothy-
roidism and hypocalcemia requiring treatment within the
first few years of life. She consented only for her samples
to be included in the study. She was reported to have
developed hypothyroidism at age 31 years, but there was
no information available regarding her thyroid antibod-
ies. She was normocalcemic and had never had symptom-
atic hypocalcemia. She was found to have a c.737TrC
transition predicted to result in the nonconservative sub-
stitution of phenylalanine by serine at amino acid 246 in
exon 10. In Ga subunits across all species, this residue is
either phenylalanine or tyrosine (Pennington 1994). The
mutation was not found in 300 unrelated chromosomes
screened.
Imprinting of NESP55 and Exon 1A Transcripts Is
Conserved in Lymphoblastoid Cell Lines
Imprinting of NESP55 and XLas has been demonstrat-
ed in a range of human fetal tissues (Hayward et al. 1998;
Hayward and Bonthron 2000), and paternal expression
of exon 1A has been demonstrated in cDNA extracted
from whole blood (Liu et al. 2000). However, skewed
imprinting and loss of imprinting in lymphoblasts have
occasionally been reported (Antequera et al. 1990; Ku-
bota et al. 1996; Hannula et al. 2001). For that reason,
we tested whether imprinting of NESP55 and exon 1A
was conserved in lymphoblastoid cell lines.
Genomic DNA from normal control lymphoblastoid
cell lines and normal fetal tissue samples was typed
for a common FokI restriction-enzyme polymorphism
(c.393T/C; I131I) in exon 5 of GNAS1. Seven lympho-
blastoid cell lines and two normal fetal tissue samples
were found to be heterozygous (/) (data not shown).
cDNA from these samples was used to amplify the
NESP55, exon 1A, and Gsa transcripts in separate
reactions, using the appropriate 5′ exon forward prim-
er and a reverse primer in exon 10 of GNAS1 (giving
three distinct products). The authenticity of the tran-
scripts was confirmed by sequencing from exon 2 back
to the 5′ exon. The three amplicons were subsequently
reamplified using nested exonic primers (a labeled for-
ward primer in exon 4 and a reverse primer in exon
6), to generate smaller fluorescently labeled products
encompassing the FokI polymorphism. The products
were digested with FokI and were sized. FokI digestion
of the initial PCR products was not attempted, because
of the complexity introduced by alternative splicing of
exon 3 and because of the presence of additional FokI
sites. As expected, Gsa transcripts were biallelically ex-
pressed in both lymphoblasts and fetal tissue. As predict-
ed, the NESP55 and exon 1A transcripts were found to
be monoallelically expressed in all the normal lympho-
blast and fetal samples. In addition, the NESP55 and
exon 1A transcripts were confirmed to be oppositely
imprinted (fig. 4).
Determining the Parental Origin of GNAS1 Mutations
The NESP55 and exon 1A transcripts were amplified
from lymphoblastoid cDNA in separate reactions, using
a forward primer in the unique 5′ exon and a reverse
primer in either exon 10 or exon 11 ofGNAS1 (according
to the mutation position). The NESP55 product was re-
amplified using nested primers, since the initial NESP55
PCR product was weak (possibly because of low copy
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Figure 2 Sequence data from patient AHO-33. A heterozygous IVS4:11ArG mutation was present in genomic DNA. Gsa cDNA
amplification products showed only normal transcript, owing to NMD of the mutant transcript, whereas amplification of the NESP55 transcript
revealed retention of intron 4. The base substitution is depicted in boldface. Intronic and exonic sequences are given in lowercase and uppercase,
respectively. Exon 4 sequence is underlined.
number in lymphoblasts). TheNESP55 and exon 1A tran-
scripts were then sequenced using internal primers span-
ning the mutation but avoiding the inclusion of exon 3
because of the complexity introduced by the alternative
splicing. The results are summarized in table 4.
In two patients, the parental origin of the mutation
was known. Patient AHO-29, with borderline low thy-
roxine, had a clinically affected mother in whom the
mutation was also demonstrated. Themutationwas con-
firmed to be present in the NESP55 transcript but not
the exon 1A transcript. The converse was found in pa-
tient AHO-11, in whom the mutation was found in the
exon 1A transcript while the NESP55 sequence was nor-
mal (fig. 3b). In this patient, a diagnosis of PPHP has
been confirmed, in the past, by normal PTH-stimulation
testing. In addition, her mutation has previously been
shown to be paternally derived, using the nearby FokI
polymorphism, for which she was informative (Wilson
et al. 1994).
The results for the remaining patients are summarized
in table 4. In each patient, the mutation was found in
either the NESP55 transcript or the exon 1A transcript
but not both. In the five patients with de novo mutations
who have confirmed PHP Ia, the paternally derived exon
1A allele showed only normal sequence, whereas the
maternally derived NESP55 allele carried only the mu-
tated sequence.
In two normocalcemic adults with AHO, neither of
whom had any history of hypocalcemia, the mutations
were found to be of paternal origin, since they were
present in the exon 1A transcript but not the NESP55
transcript.
Protein-Terminating Mutations That Were Undetectable
in the Gsa Transcript Were Detected in NESP55 cDNA
In patient AHO-17, the mutation was predicted to
result in skipping of exon 4 and a frameshift. Analysis
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Figure 3 Sequence data showing genomic DNA and NESP55 and exon 1A cDNA products. a, Patient AHO-10. The heterozygous c.565-
568delGACT deletion is present in genomic DNA, as denoted by the inverted triangle. Only deleted sequence is present in the NESP55 transcript,
and only normal sequence is present in exon 1A, indicating that theGNAS1mutation is maternally derived. b, Patient AHO-11. The heterozygous
c.4321GrA intron 5 splice-site mutation is present in genomic DNA. In NESP55 cDNA, normal exon 5 splicing has occurred. In exon 1A
cDNA, skipping of exon 5 has occurred, confirming that the GNAS1 mutation is paternally derived. Exonic sequence is given in uppercase,
and intronic sequence is given in lowercase. Exons 4, 5, and 6 sequences are given in boldfaced, normal, and underlined text, respectively.
of the Gsa mRNA showed only normal sequence, con-
sistent with reduced expression or NMD affecting the
mutant allele. Analysis of the NESP55 mRNA by using
nested amplification from the unique 5′ exon to exon 11
showed only an abnormally short product, the sequenc-
ing of which confirmed skipping of exon 4.
In patient AHO-10, who has the common c.565-
568GACT deletion, we confirmed that the mutant
Gsa mRNA was not detectable but that the 4-bp de-
letion was present in the NESP55 transcript (fig. 3a).
In patient AHO-15, with a mutation affecting the in-
tron 7 splice-acceptor site, only normal Gsa transcript
was present. Analysis of the NESP55 transcript revealed
that the weak novel splice-acceptor site 1 nt downstream
was used, resulting in a single-base deletion, which in the
Gsa transcript would be predicted to cause a frameshift
and premature termination eight codons downstream in
exon 8 (fig. 5).
In patient AHO-33, no mutation had been found on
screening of genomic DNA; however, she was hetero-
zygous for the common FokI polymorphism, and only
her paternally derived Gsa  allele could be amplified
from lymphoblast cDNA. To confirm that the FokI 
allele was maternally derived, we amplified exons 4–6
of her NESP55 cDNA by using nested PCR. The re-
sulting product was abnormally large, and sequencing
revealed that intron 4 had been retained. The only de-
monstrable alteration in the exon 4/intron 4/exon 5 se-
quence was a single-nucleotide substitution (11ArG)
at position IVS4. In retrospect, the sequence change had
resulted in an altered DHPLC elution peak of the am-
plicon encompassing exons 4 and 5. This had been dis-
counted as being unlikely to be pathological after se-
quencing and analysis using a neural network splice-
predictor program (see the Berkeley Drosophila Genome
Project Web site), which did not predict any alteration
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Figure 4 Imprinting of GNAS1 and overlapping transcripts in normal lymphoblast cell lines. The transcripts were amplified using an
upstream primer in the unique exon and a downstream primer in exon 10 of GNAS1. Because of alternative splicing of exon 3 and multiple
FokI restriction-enzyme cut sites, nested amplification from exons 4–6 was performed on each transcript prior to FokI digestion. The FokI 
allele (c.393T) gave a 195-bp product, and the FokI  allele (c.393C) gave two products, of 122 and 73 bp (only the 122-bp product was
visualized). An electropherogram demonstrating the fragments from one cell line (sized on an ABI 377 sequencer) is shown. a, Monoallelic
expression of exon 1A, with only the  allele being present. b, Biallelic expression of Gsa, with  and  alleles being present. c, Monoallelic
expression of NESP55 (opposite to exon 1A), with only the  allele being present.
Figure 5 Effect of the c.586-1GrAmutation (patientAHO-15).
The GrA substitution obliterates the normal AG acceptor site in intron
7 (underlined) and causes NMD of the mutant Gsa transcipt. Analysis
of the NESP55 transcript reveals that exon skipping does not occur.
Instead, the novel splice site created 1 nt downstream is used, resulting
in deletion of a single G nucleotide with a frameshift and premature
termination in exon 8. Consensus splice-acceptor sequence is defined
as NCAGG (Shapiro and Senapathy 1987). Intronic and exonic se-
quences are given in lowercase and uppercase, respectively.
of the 3′ splice site. No other sequence variant to explain
the inclusion of intron 4 could be found, and the IVS4:
11ArG change has not been found in 70 control chro-
mosomes. The inclusion of intron 4 in the Gsa transcript
would be predicted to result in premature truncation 21
codons downstream.
Discussion
Determining the Parental Origin of GNAS1 Mutations
We have exploited two oppositely imprinted overlap-
ping mRNA transcripts, to determine the parental origin
of GNAS1 mutations in nine patients with AHO. This
approach has previously been used to demonstrate the
parental origin of activating GNAS1 mutations in pi-
tuitary adenomas (Hayward et al. 2001). Using the ma-
ternally expressed NESP55 and paternally expressed
exon 1A transcripts, we were able (1) to confirm the
parent of origin in two patients for whom it was known
(one maternal and one paternal) and (2) to demonstrate
a maternal origin in five patients with PHP Ia. The pres-
ent study included two adults with AHO whom we had
classified as having likely PPHP, given that they were
normocalcemic and had no history of hypocalcemia.
One had developed hypothyroidism, at age 31 years, for
which she was treated with thyroxine. Her three affected
children all developed hypothyroidism between 1.5 and
4.75 years of age and hypocalcemia between 2.5 and
10.75 years of age. Her hypothyroidism could be a mild
manifestation of PHP Ia or could be coincidental; in the
absence of PTH-infusion testing, it is difficult to be sure.
Nevertheless, it is of interest that both of these individ-
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Figure 6 Splice-recognition sequences within GNAS1 intron 4.
The putative branch site GCTAAAT (underlined) is disrupted by the
IVS4:11ArG mutation (arrow). A second possible upstream branch
site, CCCTGAC, is also shown (dotted underline). The diamond sym-
bol denotes the conserved adenine nucleotide within the branch sites.
The unusually short polypyrimidine tract CATTTC is given in italics.
Exon 5 sequence is given in uppercase.
uals had mutations originating on their paternal allele
and that neither had manifested any endocrine dysfunc-
tion in childhood or early adulthood, when the onset is
typical. In fact, neither had come to medical attention
prior to the diagnosis of AHO in their children. These
results are in keeping with the observed parental-origin
effects in familial AHO (Davies and Hughes 1993; Wil-
son et al. 1994).
This method allows for the determination of parental
origin in any patient with a confirmed mutation in exons
2–13 of GNAS1. It is not applicable to patients with
mutations in exon 1, since that exon is not present in
any of the reported overlapping imprinted transcripts.
It is of potential value in patients who are heterozygous
for the common FokI polymorphism in exon 5 (i.e., in
50% of the cohort that we studied), who can quite sim-
ply be screened for the presence of NMD indicative of
a truncating mutation within that transcript. Parental
origin can be determined by typing of the NESP55 and
exon 1A transcripts for the FokI polymorphism. We be-
lieve that, in the absence of PTH-stimulation testing, this
technique could be useful for clinicians facedwith a young
patient with a de novo mutation and AHO who is nor-
mocalcemic and euthyroid at first presentation, since it
would predict the likelihood of associated PHP Ia and
would help guide the frequency of monitoring for hy-
pocalcemia and hypothyroidism.
There have been relatively few reports of paternal
transmissions of AHO, probably because normocalce-
mic, euthyroid patients are less likely to come to med-
ical attention, biasing the ascertainment. In the few
paternal transmissions that have been reported, there
is one instance in which the offspring was found to
have PTH resistance on stimulation testing (although
all baseline hormone measurements were normal), in-
dicating that the parental-origin effect may not be ab-
solute (Schuster et al. 1994). Use of the technique that
we report allows the parental origin to be determined
in most patients with sporadic disease. It could poten-
tially increase the number of patients with AHO who
have confirmed paternally derived GNAS1 mutations
for endocrine evaluation. In turn, this could help quan-
tify the predictive value of knowing the parental origin
in determining the endocrine phenotype in AHO, given
that the effect may not be absolute.
The Effects of Intronic Mutations on Splicing
Three of the mutations we report resulted in altered
mRNA splicing detectable in the NESP55 transcript.
Splice sites are characterized by a consensus nucleotide
sequence at the 5′ and 3′ ends of the intron and a further
consensus branch-site sequence upstream of the 3′ ac-
ceptor site. These sites are recognized by small nuclear
ribonuclear proteins that bind, forming a multisubunit
RNA-protein complex known as the “spliceosome.”
This facilitates cleavage at the 5′ end of the intron and
formation of a lariat at the branch site, after which the
3′ end of the intron is cleaved and the two exon ends
are ligated (Ohshima and Gotoh 1987). Branch sites
have a consensus sequence of Y81 NY100 T87 R81
A100 Y94 (where “Y” denotes pyrimidine, “R” de-
notes purine, and “N” denotes any nucleotide) (Krainer
and Maniatis 1988), although definitive identification
is often difficult. Within the branch site, the adenine
residue is thought to be essential for lariat formation
and successful splicing (Ohshima and Gotoh 1987).
In patient AHO-17, deletion of the intron 4 splice-do-
nor site was expected to result in exon 4 skipping. This
was confirmed to have occurred in theNESP55 transcript.
In patient AHO-33, the intronic mutation (IVS4:
11ArG) 11 nt upstream of the intron 4 splice-ac-
ceptor site is of particular interest. We were unable
to test whether it was de novo, because the mother
of the patient was deceased. Prior to our analysis of
the Gsa and NESP55 transcripts, testing with a splice-
predictor program had indicated that it was not likely
to be pathogenic. However, it resulted in retention of
intron 4 in the NESP55 transcript, possibly as a result
of altering the branch site. Nucleotides 10 to 16
upstream of the 3′ acceptor site of intron 4 may rep-
resent a branch site, although the sequence does not
conform exactly to the consensus (fig. 2). It is possi-
ble that the IVS4:11ArG change disrupts the con-
served adenine nucleotide, causing failure of the splice-
osome to bind or incorrect formation of the lariat dur-
ing splicing with resulting retention of intron 4 in the
mature mRNA (fig. 6).
In patient AHO-15, the 586-1GrA mutation affects
the conserved guanine residue in the 3′ acceptor site of
intron 7. The effect of most splice-acceptor site mutations
is skipping of the entire exon, which in the Gsa transcript
would have resulted in exon 8 skipping with a frameshift
and premature protein truncation in exon 9.Analysiswith
a neural network splice-predictor program (see the Berke-
ley Drosophila Genome Project Web site) showed that the
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normal 3′ acceptor site of intron 7 had a score of 0.78
(where 1.0 is the most likely splice-acceptor site). While
the 586-1GrA change could create an immediately ad-
jacent novel 3′ splice site, the predicted score for this site
was 0.28 (fig. 5). Analysis of the NESP55mRNA revealed
that splicing does indeed occur at this adjacent site, re-
sulting in deletion of a single G nucleotide (c.586delG),
a frameshift, and predicted premature protein truncation
in exon 8, rather than exon 9.
Although these splice events were the only ones we
detected, we cannot exclude the possibility that other
aberrantly spliced transcripts resulted that failed to am-
plify sufficiently for us to detect with the method used.
The Effects of Protein-Truncating Mutations on NMD
NMD is a mechanism that protects cells from muta-
tions that yield truncated, potentially deleterious pro-
teins. In mammalian cells, it appears to be largely de-
pendent on pre-mRNA splicing during which a complex
of proteins involved with the splicing or subsequent steps
of mRNA transport becomes associated 20–24 nt up-
stream of the exon-exon junctions (where they are known
as “destabilizing elements”). These proteins are stripped
from the mRNA with the first passage of the ribosome
during translation. If translation terminates prematurely,
then proteins from the downstream destabilizing complex
can interact with proteins in the normal translational ter-
mination complex and other proteins, to activate a de-
capping protein and subsequent rapid degradation of the
mRNA by intracellular 5′r3′ exonucleases (for review, see
Maquat 2002). The normal NESP55 transcript is unusual
in having so many introns within its 3′ UTR. It is believed
that the destabilizing elements do not bind 3′ to the con-
stitutive termination codon. This is likely to explain the
stability of the normal NESP55 transcript.
In patients in whom we found protein-truncating mu-
tations, only normal Gsa transcript was found. The sim-
plest explanation is that the mutations resulted in NMD
of the mutant transcript, but we cannot exclude the pos-
sibility that low levels of mutant Gsa transcript were
obscured by preferential amplification and detection of
the normal allele. In each instance, we were able to con-
sistently detect a mutant NESP55 transcript that, had
the Gsa transcript been processed in the same way,
would have been expected to result in protein truncation.
It is likely that the mutant NESP55 transcript was not
subject to NMD because the mutations lay within the
3′ UTR. Nevertheless, it may be that our ability to detect
the mutant NESP55 transcripts was more sensitive as a
result of the monoallelic expression, rather than any in-
creased stability compared to the mutant Gsa transcript.
To detect the NESP55 transcript, even in the normal
control lymphoblast cell lines, we found that it was nec-
essary to perform a nested amplification, which is likely
to reflect a low copy number in lymphocytes but may
also have improved our detection of mutant NESP55 as
compared to Gsa transcripts.
A Useful Model System for Analyzing the Effects
on mRNA of Sequence Changes That Usually
Result in NMD
It is well recognized that the classification of sequence
changes as missense, frameshift, or splicing mutations
can be inaccurate when based on inspection of the se-
quence alone. When possible, analysis of the mutant
mRNA is desirable. Although the observation of NMD
in many instances indicates the introduction of a prema-
ture termination codon, it obscures the precise effect that
the mutant sequence has on themRNA and its processing.
In the patients with splicing and protein-truncating mu-
tations whom we studied, the effects of the mutations
were revealed through analysis of the NESP55 transcript.
On the basis of our findings, we believe that the GNAS1
overlapping imprinted gene cluster represents an inter-
esting model system for detailed study of the effects that
altered intronic and exonic sequences have on mRNA
splicing, since any mutation downstream of GNAS1 ex-
on 1 is likely to be detectable in either the NESP55 or the
exon 1A transcript, despite NMD of the Gsa transcript.
Genotype-Phenotype Correlations in AHO
GNAS1 mutations have the potential to affect the
overlapping transcripts differently, depending on wheth-
er they occur in exon 1 or exons 2–13 and whether they
occur on the maternal allele or the paternal allele. Mu-
tations of exons 2–13 might be expected to have addi-
tional manifestations, given that they affect the overlap-
ping transcripts as well. It seems unlikely that mutations
of the maternal allele will exert any additional effects
through alterations of NESP55. It is not yet clear whether
paternally derived mutations in exons 2–13 will affect the
function of the exon 1A transcript, but they would be
expected to impair XLas. Careful molecular and clinical
characterization of patients may reveal some genotype-
phenotype correlations in future, but, to date, there has
been no obvious effect, other than that of parental origin
on endocrine dysfunction.
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